Study Title | A Phase I/II Study of Nivolumab in Combination with 5-azacytidine in pediatric patients with relapsed/refractory acute myeloid leukemia |
---|---|
Protocol ID | T2016-002 |
Disease (Sub Disease) | Leukaemia (AML) |
Diagnosis Stage | Relapsed/ refractory |
Sponsor | Therapeutic Advances in Childhood Leukemia Consortium |
Collaborators | Bristol-Myers Squibb |
Links | https://clinicaltrials.gov/ct2/show/NCT03825367 |
Trial Status | Closed to Recruitment |
Trial Open Date | 22/11/2021 |
Study Type | Treatment |
Phase | Phase 1/2 |
Age Eligibility | 1 Year to 30 Years |
International registry ID's | NCT03825367 |